Recommend Cell Cycle to your librarian for 2008. Download form here.

Sign up for Table of Contents Alerts.

home subscribe search archive forthcoming

Email this page Print this page

Perspectives

Ras and Phosphoinositide 3-Kinase: Partners in Development and Tumorigenesis

Antoine R. Ramjaun and Julian Downward

volume 6 | issue 23

1 December 2007
Pages: 2902 - 2905

Purchase article for $19

Subscribe to this journal for $129/year

Much progress has been made in understanding the myriad of intracellular signalling pathways responsible for control of cell physiology. Signalling downstream of receptor tyrosine kinases (RTKs) is probably the most studied signalling mechanism to date and many of the molecular components and corresponding interactions involved have been delineated. Importantly, deregulation of RTK signalling has been implicated in the formation and maintenance of many human tumours. Two of the pivotal molecular components in RTK signalling, Ras and phosphoinositide 3-kinase (PI 3-kinase), have been shown to bind to each other, leading to the activation of PI 3-kinase. However, in addition to this Ras - PI 3-kinase interaction, first described over a decade ago, several other molecular interactions have more recently been described that appear to mediate the same signal. This has brought into question the physiological relevance of the Ras – PI 3-kinase interaction during RTK signalling. Through disruption of the interaction in a mouse model, we have now confirmed that the interaction is highly functional in vivo both during mammalian development and during Ras-induced tumorigenesis. Many questions still remain: in this Perspective, we explore the remaining uncertainties surrounding the role of this signalling mechanism, as well as the future directions that will likely shed further light on its role within cells.

Authors

Antoine R. Ramjaun

Cancer Research UK; London, UK

Julian Downward

Cancer Research UK London Research Institute; London, UK


Purchase article for $19

Subscribe to this journal for $129/year